Endostar for Locally Recurrent Nasopharyngeal Carcinoma
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Nasopharyngeal Carcinoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Both males and females
Description
Locally recurrent nasopharyngeal carcinoma (NPC) may be salvaged by intensity modulated-radiotherapy (IMRT), but severe late toxicities become the most common reason of death in IMRT salvaged NPC patients. The aim of this phase II randomized controlled study is to address the efficacy of concurrent ...
Locally recurrent nasopharyngeal carcinoma (NPC) may be salvaged by intensity modulated-radiotherapy (IMRT), but severe late toxicities become the most common reason of death in IMRT salvaged NPC patients. The aim of this phase II randomized controlled study is to address the efficacy of concurrent Endostar (Endostatins) with IMRT to reduce the occurrence of severe late toxicities compared with IMRT alone for locally recurrent NPC patients.
Tracking Information
- NCT #
- NCT02636231
- Collaborators
- JiangXi Province Tumor Hospital
- The First Affiliated Hospital of Clinical Medicine of G.D.P.U.
- Second Affiliated Hospital of Nanchang University
- First People's Hospital of Foshan
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
- The Affiliated Ganzhou Hospital of Nanchang University
- The First Hospital of Gannan Medical University
- Investigators
- Principal Investigator: Fei Han, M.D., Ph.D. China: Ethics Committee
Get Well Soon